137 related articles for article (PubMed ID: 34984436)
1. SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma.
Guo T; Wei R; Dean DC; Hornicek FJ; Duan Z
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34984436
[TBL] [Abstract][Full Text] [Related]
2. Commentary on: SMARCB1 as a novel diagnostic and prognostic biomarker for osteosarcoma.
Sergi CM
Biosci Rep; 2022 Jun; 42(6):. PubMed ID: 35583077
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma.
Liu W; Zhao X; Zhang YJ; Fang GW; Xue Y
J Int Med Res; 2018 Mar; 46(3):975-983. PubMed ID: 29115164
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and Prognostic Significance of Dysregulated Expression of Circular RNAs in Osteosarcoma.
Zhang C; He J; Qi L; Wan L; Wang W; Tu C; Li Z
Expert Rev Mol Diagn; 2021 Feb; 21(2):235-244. PubMed ID: 33428501
[TBL] [Abstract][Full Text] [Related]
5. Identification of plasma microRNA-22 as a marker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma.
Diao ZB; Sun TX; Zong Y; Lin BC; Xia YS
J Int Med Res; 2020 Dec; 48(12):300060520967818. PubMed ID: 33284712
[TBL] [Abstract][Full Text] [Related]
6. Meningeal SWI/SNF related, matrix-associated, actin-dependent regulator of chromatin, subfamily B member 1 (SMARCB1)-deficient tumours: an emerging group of meningeal tumours.
Dadone B; Fontaine D; Mondot L; Cristofari G; Jouvet A; Godfraind C; Varlet P; Ranchère-Vince D; Coindre JM; Gastaud L; Baudoin C; Peyron AC; Thyss A; Coutts M; Michiels JF; Pedeutour F; Burel-Vandenbos F;
Neuropathol Appl Neurobiol; 2017 Aug; 43(5):433-449. PubMed ID: 27732747
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas9 screening identified lethal genes enriched in necroptosis pathway and of prognosis significance in osteosarcoma.
Cheng L; Xiong W; Li S; Wang G; Zhou J; Li H
J Gene Med; 2023 Dec; 25(12):e3563. PubMed ID: 37421290
[TBL] [Abstract][Full Text] [Related]
8. SLC19A1 May Serve as a Potential Biomarker for Diagnosis and Prognosis in Osteosarcoma.
Li C; Yuan B; Yu X; Ju L; Ma Y; Guo D; Zhang K
Clin Lab; 2020 Nov; 66(11):. PubMed ID: 33180421
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of SOX9 in osteosarcoma and its association with tumor progression and patients' prognosis.
Zhu H; Tang J; Tang M; Cai H
Diagn Pathol; 2013 Nov; 8():183. PubMed ID: 24188461
[TBL] [Abstract][Full Text] [Related]
10. Decreased microRNA-452 expression and its prognostic significance in human osteosarcoma.
Li RZ; Wang LM
World J Surg Oncol; 2016 May; 14():150. PubMed ID: 27193084
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA CRNDE functions as a diagnostic and prognostic biomarker in osteosarcoma, as well as promotes its progression via inhibition of miR-335-3p.
Yu Y; Wang L; Li Z; Zheng Y; Shi Z; Wang G
J Biochem Mol Toxicol; 2021 May; 35(5):e22734. PubMed ID: 33522065
[TBL] [Abstract][Full Text] [Related]
12. Combined microRNA-340 and ROCK1 mRNA profiling predicts tumor progression and prognosis in pediatric osteosarcoma.
Cai H; Lin L; Cai H; Tang M; Wang Z
Int J Mol Sci; 2014 Jan; 15(1):560-73. PubMed ID: 24398981
[TBL] [Abstract][Full Text] [Related]
13. CBX2 is a functional target of miRNA let-7a and acts as a tumor promoter in osteosarcoma.
Han Q; Li C; Cao Y; Bao J; Li K; Song R; Chen X; Li J; Wu X
Cancer Med; 2019 Jul; 8(8):3981-3991. PubMed ID: 31150156
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of serum miR-194 predicts poor prognosis in osteosarcoma patients.
Shi L; Xie C; Zhu J; Chen X
Ann Diagn Pathol; 2020 Jun; 46():151488. PubMed ID: 32172218
[TBL] [Abstract][Full Text] [Related]
15. [Expressions of ERCC2 and ERCC4 genes in osteosarcoma and peripheral blood lymphocytes and their clinical significance].
Li X; Guo W; Shen DH; Yang RL; Liu J; Zhao H
Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Oct; 39(5):467-71. PubMed ID: 17940561
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of CD24 is associated with tumor progression and prognosis in patients suffering osteosarcoma.
Tang J; Cai H; Lin L; Xie P; Zhong W; Tang M
Clin Transl Oncol; 2013 Jul; 15(7):541-7. PubMed ID: 23143956
[TBL] [Abstract][Full Text] [Related]
17. T-LAK cell-originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma.
Thanindratarn P; Wei R; Dean DC; Singh A; Federman N; Nelson SD; Hornicek FJ; Duan Z
Mol Oncol; 2021 Dec; 15(12):3721-3737. PubMed ID: 34115928
[TBL] [Abstract][Full Text] [Related]
18. Development of an immune-related prognostic index associated with osteosarcoma.
Yin CD; Hou YL; Liu XR; He YS; Wang XP; Li CJ; Tan XH; Liu J
Bioengineered; 2021 Dec; 12(1):172-182. PubMed ID: 33371790
[TBL] [Abstract][Full Text] [Related]
19. Expression and Clinical Significance of High-Mobility Group AT-hook 2 (HMGA2) in Osteosarcoma.
Cui J; Dean D; Hornicek FJ; Yi G; Duan Z
Orthop Surg; 2022 May; 14(5):955-966. PubMed ID: 35388973
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and prognostic value of NADPH oxidase 2 (NOX2) in primary osteosarcoma.
Lin RJ; Huang Z; Wang SL; Chen H; Wei HX; Shen RK; Yang LY; Lin JH
J Orthop Sci; 2021 May; 26(3):466-472. PubMed ID: 32402505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
